Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
227 Clinical Trials near Orangeburg, SC
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
OPN-375 for Nasal Polyps
Orangeburg, South CarolinaThis trial tests a nasal spray used regularly in adolescents with nasal polyps. The spray aims to shrink the polyps and reduce nasal congestion, helping them breathe more easily.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cystic Fibrosis, Glaucoma, Others
Must Not Be Taking:XHANCE, Nucala, Cinquair, Others
120 Participants Needed
Povetacicept for IgA Nephropathy
Orangeburg, South CarolinaThe purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Rapidly Progressive Glomerulonephritis, Others
Must Be Taking:ACEi, ARBs
480 Participants Needed
MK-7240 for Ulcerative Colitis
Orangeburg, South CarolinaThis trial is testing tulisokibart, a new medication, to see if it can help people with moderately to severely active ulcerative colitis. The goal is to determine if tulisokibart can reduce inflammation and heal sores in the colon, leading to fewer symptoms. The study will compare different doses of tulisokibart over several months.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:16 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Crohn's Disease, Fulminant Colitis, Cancer, Others
1020 Participants Needed
Guselkumab for Ulcerative Colitis
Orangeburg, South CarolinaThis trial tests an injectable medication called guselkumab on people with severe ulcerative colitis. It aims to see if blocking a protein that causes inflammation can help these patients achieve remission.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
418 Participants Needed
Sirogen for Arteriovenous Fistula Outcomes
Orangeburg, South CarolinaThe primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:65+
Sex:All
136 Participants Needed
Obicetrapib for Cardiovascular Disease
Orangeburg, South CarolinaThis trial is testing a new medication called Obicetrapib to help people with heart disease who still have high cholesterol despite taking strong treatments. The goal is to see if this medication can lower their risk of heart attacks, strokes, and other serious heart problems by reducing bad cholesterol levels.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
9541 Participants Needed
Finerenone for Chronic Kidney Disease
Orangeburg, South CarolinaThis trial is testing finerenone, a daily pill, to help people with non-diabetic chronic kidney disease. Finerenone works by blocking a hormone called aldosterone that can cause damage and swelling in the heart and kidneys. The goal is to see if finerenone can slow down the worsening of kidney disease. Finerenone has shown promise in reducing kidney disease progression in patients with chronic kidney disease and type 2 diabetes.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
1584 Participants Needed
Mirikizumab for Crohn's Disease
Orangeburg, South CarolinaThis trial is testing mirikizumab to see if it can help people with Crohn's disease feel better over a long time and ensure it is safe. The drug works by reducing gut inflammation.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
778 Participants Needed
Guselkumab for Ulcerative Colitis
Orangeburg, South CarolinaThis trial is testing guselkumab, a medication that targets inflammation, in patients with moderate to severe ulcerative colitis. Guselkumab works by attaching to a protein to reduce inflammation in the colon. This medication has shown promise in treating conditions like ulcerative colitis.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:18+
Sex:All
1064 Participants Needed
Bimekizumab for Psoriatic Arthritis
Orangeburg, South CarolinaThis trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
1131 Participants Needed
HAV vs AVF for Hemodialysis Access
Orangeburg, South CarolinaThe main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
240 Participants Needed
Long-Term Safety of Filgotinib for Rheumatoid Arthritis
Orangeburg, South CarolinaThis trial aims to check the ongoing safety and tolerability of filgotinib, a medication that helps reduce inflammation and pain. The study focuses on people with rheumatoid arthritis who have already used filgotinib in a previous study. Filgotinib works by blocking enzymes that cause inflammation, helping to reduce swelling and pain. Filgotinib has been approved for the treatment of rheumatoid arthritis in adults who respond inadequately to other treatments in Europe and Japan.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
2731 Participants Needed
Long-Term Filgotinib for Ulcerative Colitis
Orangeburg, South CarolinaThis trial aims to observe the safety of filgotinib in adults with ulcerative colitis who were part of an earlier study. Filgotinib reduces inflammation by blocking certain proteins. The goal is to ensure it is safe for extended use.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
1173 Participants Needed
Retatrutide for Obesity
Orangeburg, South CarolinaThe main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+
Sex:All
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Recent Heart Attack, Others
10000 Participants Needed
Targeted Therapies for Crohn's Disease
Orangeburg, South CarolinaCrohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD.
The medicines assessed in this study are risankizumab, ABBV-382 and lutikizumab. When participants join the study, they will be randomized into available study treatment groups. Adult participants with CD will be enrolled. Around 500 participants will be enrolled in the study at approximately 300 sites worldwide.
Risankizumab and ABBV-382 are given as an injection under the skin or as an infusion into the vein. Lutikizumab is given as an injection under the skin. Each group includes a 12-week induction period, a 12-week maintenance period, and an optional long-term extension period where medication will be given after the maintenance period.
There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, endoscopies, checking for side effects and completing questionnaires and a daily diary.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Ulcerative Colitis, Ostomy, Others
Must Not Be Taking:P19 Inhibitors
500 Participants Needed
Nipocalimab for Myositis
Orangeburg, South CarolinaThis trial is testing Nipocalimab, a medicine that blocks harmful antibodies, in patients with muscle weakness and other issues due to idiopathic inflammatory myopathies (IIM). The goal is to see if it can improve their condition by lowering harmful antibody levels.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
36 Participants Needed
TAK-279 for Crohn's Disease
Orangeburg, South CarolinaCrohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation.
The participants will be treated with TAK-279 for 52 weeks (1 year).
During the study, participants will visit their study clinic 15 times.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Ulcerative Colitis, Ostomy, Others
268 Participants Needed
NRD135SE.1 for Peripheral Neuropathy
Orangeburg, South CarolinaThis trial tests a daily pill called NRD135S.E1 for people with painful nerve damage from diabetes. The study will see if taking this pill for a few months can safely reduce their pain. Researchers aim to understand how well the drug works and if it is safe to use.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
122 Participants Needed
SelfWrap for Chronic Kidney Disease
Orangeburg, South CarolinaThis is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Congestive Heart Failure, Infection, Others
200 Participants Needed
InnAVasc Graft Implant for Kidney Failure
Orangeburg, South CarolinaThe goal of the CSP-2002 clinical trial is to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD). The primary study endpoints are:
Primary Effectiveness Endpoint: The proportion of subjects with secondary patency at 6 months.
Primary Safety Endpoint: The incidence of device-related adverse events of special interest (AESIs) through 6 months.
Participants will be asked to sign an informed consent form. Once enrolled, they will be assessed to receive the study graft implant and asked to participate in periodic follow-up visits and assessments through 2 years following implant.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Cardiac Disease, Uncontrolled Diabetes, Severe Peripheral Arterial Disease, Others
Must Be Taking:Antiplatelet Therapy
105 Participants Needed
EchoMark/EchoSure for Arteriovenous Fistula
Orangeburg, South CarolinaThis is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 84
Sex:All
Key Eligibility Criteria
Disqualifiers:Steal Syndrome, Immunocompromised, Active Infection, Others
304 Participants Needed
Proton Therapy vs. Photon Radiation for Prostate Cancer
Orangeburg, South CarolinaThis study is a large, prospective, pragmatic, controlled comparison of patient-centric outcomes \[quality of life (QOL), toxicity, and disease control\] between parallel cohorts of men with prostate cancer treated simultaneously at proton therapy facilities and at geographically similar conventional (photon-based) radiation facilities using intensity-modulated radiation therapy (IMRT) techniques.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:30 - 85
Sex:Male
3000 Participants Needed
Nurse-Family Partnership for Maternal Behavior
Orangeburg, South CarolinaThis study evaluates the effects of the Nurse Family Partnership (NFP), an established home-visiting program, using a scientifically rigorous individual-level randomized controlled trial. The study will be based in South Carolina, where a Medicaid waiver in combination with a pay-for-success contract will allow expansion of the program to women on Medicaid. The study plans to enroll 4000 low-income, first time mothers and their children into the intervention group, and another 2000 into the control group. The study will evaluate the program's impacts on outcomes using administrative records. This study aims to yield new evidence on the effect of NFP in a modern context, applied to a new population, across a broad range of outcomes, and financed by a novel public-private partnership based on accountability for outcomes.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:15 - 55
Sex:Female
5820 Participants Needed
LYR-210 for Chronic Sinusitis
Orangeburg, South CarolinaMulticenter, phase III, randomized, blinded, controlled, parallel group.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
182 Participants Needed
RPC1063 for Ulcerative Colitis
Orangeburg, South CarolinaThe purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis. Only those participants who have previously participated in a trial of RPC1063, being either RPC01-3101 or completed at least 1 year of the open-label period of RPC01-202 will be eligible.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
878 Participants Needed
ISA-Specific Therapy for Diabetic Nerve Pain
Orangeburg, South CarolinaThis trial tests several treatments for nerve pain in diabetic patients to identify effective therapies for reducing this type of pain.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
122 Participants Needed
Anti-Factor XI Monoclonal Antibody for Kidney Failure
Orangeburg, South CarolinaThis trial is testing MK-2060, a medicine that blocks a blood protein, on patients with severe kidney disease. The goal is to see if it can prevent clots and keep the treatment method effective for a longer period.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
506 Participants Needed
Inclisiran for Cardiovascular Disease
Columbia, South CarolinaThis trial is testing inclisiran, an injectable drug, on people with heart disease who are already on strong cholesterol-lowering medications. The goal is to see if inclisiran can further reduce the risk of heart attacks and strokes by lowering bad cholesterol levels. Participants will receive the injection periodically. Inclisiran works by significantly reducing bad cholesterol levels.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Sex:All
17004 Participants Needed
Atorvastatin for Preventing Dementia
Columbia, South CarolinaPREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:75+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Dementia, ADL Dependence, Others
Must Not Be Taking:Statins
20000 Participants Needed
Pentoxifylline for Diabetic Kidney Disease
Columbia, South CarolinaPentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Organ Transplant, Others
Must Not Be Taking:Pentoxifylline, Ketorolac, Riociguat
2510 Participants Needed
Page 1 of 8+
Frequently Asked Questions
How much do clinical trials in Orangeburg, SC pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do clinical trials in Orangeburg, SC work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Orangeburg, SC 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Orangeburg, SC is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Orangeburg, SC several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a medical study in Orangeburg, SC ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest clinical trials in Orangeburg, SC ?
Most recently, we added Social Media Intervention for Opioid Abuse, ALKS 2680 for Idiopathic Hypersomnia and Exercise for Arthritis to the Power online platform.